News & Research - HBM Partners AG

NEWS & RESEARCH

Portfolio News

HBM in the News

Industry Reports

Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million (99 KB)
16.9.2020
Download
Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing (18 KB)
15.9.2020
Download
NiKang Therapeutics Completes $50 Million Series B Financing (150 KB)
14.9.2020
Download
Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA (20 KB)
8.9.2020
Download
Andrew Hirsch Named Chief Executive Officer of C4 Therapeutics (109 KB)
8.9.2020
Download
Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs (200 KB)
24.8.2020
Download
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio (1024 KB)
24.8.2020
Download
iTeos Therapeutics Announces Pricing of Initial Public Offering (17 KB)
23.7.2020
Download
SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors (28 KB)
22.7.2020
Download
Bioatla Raises $72.5 Million in Series D Financing (98 KB)
15.7.2020
Download

<2 3 456 7 >

Biotech strebt in Rekordzahl an die Börse - aus der «Finanz und Wirtschaft» (1907 KB)
16.03.2021
Download Read more
Aktiver Ansatz zahlt sich aus - aus der «Finanz und Wirtschaft» Nr. 16 (2217 KB)
27.02.2021
Download Read more
Das Derby der Impfstoffhersteller (163 KB)
16.11.2020
Download Read more
Gewinne aus dem Labor (310 KB)
01.11.2020
Download Read more
Andreas Wicki, CEO HBM Healthcare Investments AG “The importance of biotech as the backbone of innovation of the pharma industry is growing all the time.” (156 KB)
18.08.2020
Download Read more
«Bedeutung von Biotech als Innovations-Rückgrat der Pharma-Industrie nimmt stetig zu» (196 KB)
18.08.2020
Download Read more
Biotech im Hoch: Nicht alle Healthcare-Unternehmen kommen gleich durch die Corona-Krise (499 KB)
25.07.2020
Download Read more
Virus eröffnet Anlage-Chancen (100 KB)
2.4.2020
Download Read more
Pharmaprofis kaufen keine Corona-Aktien (123 KB)
1.4.2020
Download Read more
Der Bedarf der Pharmakonzerne nach neuen Medikamenten ist ungestillt - Interview Dr. Andreas Wicki (302 KB)
6.11.2019
Download Read more
Investing in biotechnology - a lucrative approach (304 KB)
1.9.2019
Download Read more
Investieren in die Biotechnologie – ein aktiver Ansatz zahlt sich aus (4594 KB)
1.9.2019
Download Read more
Interview with Andreas Wicki (351 KB)
Download Read more
Interview with Ivo Staijen (263 KB)
17.7.2019
Download Read more
Biotech-Unternehmen schwimmen im Geld (309 KB)
25.5.2019
Download Read more
„Ungebremste Innovationskraft" (628 KB)
1.5.2019
Download Read more
Unbridled Capacity for Innovation (101 KB)
1.5.2019
Download Read more
Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)
23.1.2019
Download Read more
Investing in listed private equity – more than just an alternative (197 KB)
23.1.2019
Download Read more
Kleine Hersteller, grosses Potenzial (1007 KB)
1.1.2019
Download Read more

Trends in New Drug Approvals

Report covers new drugs approved by US FDA. The latest report as well as a list of new drug approvals since 2003 are available for download.

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)
Download
FDA Approved NMEs 2003-2018 (86 KB)
Download

HBM Pharma/Biotech M&A Report

HBM Partners carries out an ongoing analysis of all trade sales of public and private US and European biotech and pharma companies. The latest HBM Pharma/Biotech M&A Report as well as information on M&A transactions since 2005 are available for download:

Credits

Sitemap

Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million (99 KB)

Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing (18 KB)

NiKang Therapeutics Completes $50 Million Series B Financing (150 KB)

Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA (20 KB)

Andrew Hirsch Named Chief Executive Officer of C4 Therapeutics (109 KB)

Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs (200 KB)

Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio (1024 KB)

iTeos Therapeutics Announces Pricing of Initial Public Offering (17 KB)

SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors (28 KB)

Bioatla Raises $72.5 Million in Series D Financing (98 KB)

Biotech strebt in Rekordzahl an die Börse - aus der «Finanz und Wirtschaft» (1907 KB)

Aktiver Ansatz zahlt sich aus - aus der «Finanz und Wirtschaft» Nr. 16 (2217 KB)

Das Derby der Impfstoffhersteller (163 KB)

Gewinne aus dem Labor (310 KB)

Andreas Wicki, CEO HBM Healthcare Investments AG “The importance of biotech as the backbone of innovation of the pharma industry is growing all the time.” (156 KB)

«Bedeutung von Biotech als Innovations-Rückgrat der Pharma-Industrie nimmt stetig zu» (196 KB)

Biotech im Hoch: Nicht alle Healthcare-Unternehmen kommen gleich durch die Corona-Krise (499 KB)

Virus eröffnet Anlage-Chancen (100 KB)

Pharmaprofis kaufen keine Corona-Aktien (123 KB)

Der Bedarf der Pharmakonzerne nach neuen Medikamenten ist ungestillt - Interview Dr. Andreas Wicki (302 KB)

Investing in biotechnology - a lucrative approach (304 KB)

Investieren in die Biotechnologie – ein aktiver Ansatz zahlt sich aus (4594 KB)

Interview with Andreas Wicki (351 KB)

Interview with Ivo Staijen (263 KB)

Biotech-Unternehmen schwimmen im Geld (309 KB)

„Ungebremste Innovationskraft" (628 KB)

Unbridled Capacity for Innovation (101 KB)

Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)

Investing in listed private equity – more than just an alternative (197 KB)

Kleine Hersteller, grosses Potenzial (1007 KB)

Trends in New Drug Approvals

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)

FDA Approved NMEs 2003-2018 (86 KB)

HBM Pharma/Biotech M&A Report

Biopharma M&A Update H1 2019 and Potential Implications of Mega Mergers for Smaller Biopharma Deal Making (470 KB)

HBM Pharma / Biotech M&A Report 2020 (1299 KB)

Pharma / Biotech M&A Transctions 2005-2019 (119 KB)